Lipophenolic compounds for use in the treatment of viral infections and diseases of the central nervous system.
Patent Information
- Application Number
- DE602018092404
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-11-10
- Filing Date
- 2018-11-12
- Publication Date
- 2026-07-15
- Estimated Expiration
- 2038-11-12
AI Technical Summary
Current treatments for diseases or disorders associated with exacerbated vascular, lymphatic, or mucosal permeability, such as those caused by infectious agents like Dengue or Ebola virus, lack effective MMP-9 inhibitors due to poor bioavailability of existing compounds like resveratrol.
Development of lipophenolic compounds, particularly resveratrol derivatives with fatty acid chains at specific positions, which enhance MMP-9 inhibition activity, protecting endothelial barriers and reducing permeability.
The lipophenolic compounds effectively inhibit MMP-9 activity, reducing vascular, lymphatic, or mucosal permeability, and are suitable for short-term treatment of acute conditions and chronic disorders, including viral hemorrhagic fevers and central nervous system disorders.